FDA approves Alzheimer's drug that slowed cognitive decline in clinical trial
Publishing timestamp: 2023-01-06 19:10:09
Summary
The FDA approved a new Alzheimer's drug called lecanemab, developed by Biogen and Eisai, which slows cognitive decline in people with mild impairment from Alzheimer's. The drug carries risks of brain swelling and bleeding and will cost $26500 per year in the US. The approval comes after a congressional report last week about the controversial approval of another Alzheimer's drug developed by Biogen and Eisai. The lecanemab is a monoclonal antibody that targets a protein called amyloid which builds up on the brain in people with Alzheimer's. The FDA approved the drug based on reduction of amyloid plaque observed in clinical trial participants who received treatment.
Sentiment: NEUTRAL
Keywords: eisai co ltd, biogen inc, breaking news: politics, politics, biotech and pharmaceuticals, pandemics, business, breaking news: business, business news, epidemics, biotechnology, health care industry, coronavirus, u.s. economy, disease outbreaks,